AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development ...

Samit Hirawat, chief medical officer at Bristol Myers Squibb, talks about his leading role in BMS’ $300M, five-year plan to expand its efforts in health equity and his career-long commitment to ...

Samit Hirawat Yes. So, our TIGIT inhibitor is in Phase 1 study, defining the dose and the safety and the profile of the medicine to see if there are signals of activity that we can start to see.

The approval of Biogen Inc.’s Aduhelm clarifies the U.S. Food and Drug Administration’s standard for drugs for neurodegenerative diseases, making it easier to design studies for new therapies ...

For the biopharma industry, 2020 was many things, but for Samit Hirawat, M.D., chief medical officer of Bristol Myers Squibb, three things stand out: collaboration, adaptation and evolution.

Samit Hirawat, the Executive Vice President and Chief Medical (TASE: BLWV) Officer for Drug Development at Bristol Myers Squibb Co. (NYSE: BMY), recently acquired shares in the company. According to a ...

SAMIT HIRAWAT (EVP,Chief Med.Offr.,Drug Dev.) has made 2 purchases buying 3,653 shares for an estimated $200,055 and 0 sales. PHIL M HOLZER (SVP and Controller) sold 700 shares for an estimated ...